CALCULATE YOUR SIP RETURNS

Morepen Laboratories Launches Empamore For Affordable Diabetes Treatment

Written by: Team Angel OneUpdated on: Mar 18, 2025, 4:27 PM IST
Morepen Laboratories has launched Empamore, a new and affordable treatment for Type 2 Diabetes, Heart Failure and Chronic Kidney Disease at a lower cost.
Morepen Laboratories Launches Empamore For Affordable Diabetes Treatment
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Morepen Laboratories has introduced Empamore, a new medication designed to treat Type 2 Diabetes, Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. India has a high number of diabetes cases with over 101 million people affected. Empamore aims to offer an affordable and high-quality treatment to help people manage their health better.

Affordable and Effective Treatment

Empamore contains Empagliflozin, a well-known medicine for diabetes control. Morepen produces this at its USFDA-approved facility, ensuring global quality standards. The product range includes:

  • Empamore (10mg/25mg)
  • Empamore M (12.5mg of Empagliflozin with 500mg/1000mg Metformin)

With diabetes cases in India rising, Morepen’s cost-effective solution makes quality treatment more accessible.

Making Healthcare Affordable for Everyone

Morepen aims to reduce financial stress for diabetes patients by selling Empamore at 90% lower costs compared to existing brands. The company focuses on expanding healthcare access by ensuring the medicine is widely available at reasonable prices. Ashutosh Sharma, Vice President of Sales & Marketing at Morepen Laboratories, expressed during the launch, “At Morepen, we are dedicated to democratizing healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without Financial strain. This aligns with our commitment to empower people to take charge of their health.”

Morepen’s Contribution to Diabetes Care

Morepen has a strong history in diabetes management, having installed over 12.33 million glucometers and sold 1.65 billion blood glucose strips. With a global presence in 82 countries, the company continues to innovate and bring affordable healthcare solutions to both India and the world.

Share performance 

As of March 18, 2025, at 1:30 PM, the shares of Morepen Laboratories Ltd are trading at ₹48.99 per share, reflecting a profit of 14.36% from the previous day’s closing price. Over the past month, the stock has registered a loss of 1.90%. The stock’s 52-week high stands at ₹100.90 per share, while its low is ₹40.20 per share.

Conclusion

Empamore is a step towards affordable and accessible healthcare for diabetes patients. By providing cost-effective and high-quality treatment, Morepen is making it easier for people to manage their health without financial strain.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Mar 18, 2025, 4:27 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers